Nebivolol Actavis (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Actavis, is a beta‑adrenergic blocker presented as a tablet for oral use. It selectively blocks β1‑adrenergic receptors and enhances nitric‑oxide release, helping to lower elevated blood pressure in adult patients diagnosed with hypertension. The drug is part of standard antihypertensive therapy in many European treatment guidelines.

GNH USA supplies Nebivolol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory conformity across all markets, through reliable logistics and dedicated customer support.

Nebivolol is a selective β1‑adrenergic blocker used in the management of high‑blood‑pressure disorders.

Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. Stage 1 hypertension: achieves target blood pressure levels in early‑stage disease. Stage 2 hypertension: provides additional pressure control in more severe hypertension.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported during therapy. - Dizziness: transient light‑headedness, especially after first doses. - Fatigue: feeling of tiredness or reduced energy. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: significant drop in blood pressure leading to fainting. - Bronchospasm: airway constriction, particularly in patients with asthma. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Nebivolol, clinicians should observe several precautionary measures to ensure safe use.

- Blood pressure monitoring: check baseline and periodic readings to assess response. - Heart rate assessment: evaluate resting heart rate before initiation and during therapy. - Asthma caution: avoid use in patients with active bronchospastic disease. - Discontinuation: do not stop abruptly; taper to prevent rebound hypertension. - Renal impairment: adjust dose in patients with moderate to severe renal dysfunction. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: combined use may cause excessive bradycardia and hypotension. - Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): increase risk of heart block and slowed conduction. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol plasma levels, enhancing adverse effects.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive blood‑pressure lowering effect, monitor for hypotension. - Diuretics: may potentiate orthostatic hypotension, observe fluid status. - Antidiabetic agents: beta‑blockade can mask hypoglycaemia symptoms, check glucose regularly.